Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.62 |
| ▸ | EGFR | P00533 | 7/20 | 0.60 |
| ▸ | AURKA | O14965 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490057 | 0.92 | AURKA (0.64) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4286868 | 0.87 | AURKA (0.76) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3490157 | 0.87 | AURKA (0.57) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3489277 | 0.83 | KDR (0.50) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5025166 | 0.83 | AURKA (0.73) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12342162 | 0.80 | KDR (0.52) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4289085 | 0.79 | AURKA (0.83) | AURKAAURKB | |
| SCHEMBL13749942 | 0.79 | SRC (0.52) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4287185 | 0.77 | AURKA (0.85) | KDREGFRAURKAABL1LCK | |
| SCHEMBL4286835 | 0.77 | AURKA (0.82) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1463506-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | Astrazeneca AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | KDR 933/4885HDAC3 1090/4885HDAC4 911/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | KDR 960/4885HDAC3 870/4885HDAC4 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.